In Vivo:Article Title: Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Article Snippet: Representative melanoma cell line M14 (NCI-DTP Cat# M14, RRID:CVCL_1395), small cell lung cancer cell line NCI-N87 (ATCC Cat# CRL-5822, RRID:CVCL_1603), human leukemia cell line HL6 (ATCC Cat# CCL-240, RRID:CVCL_0002), breast cancer cell line HCC1954 (ATCC Cat# CRL-2338, RRID:CVCL_1259), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), and hepatoblastoma cell line Hep-G2 (ATCC Cat# HB-8065, RRID:CVCL_0027) were purchased.. All the cell lines used were authenticated by short tandem repeat profiling with PowerPlex V.1.2 System (Promega), and periodically tested for mycoplasma infection using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).All the cell lines used were authenticated by short tandem repeat profiling with PowerPlex V.1.2 System (Promega), and periodically tested for mycoplasma infection using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).
Article Title: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Article Snippet: Representative melanoma cell line M14 (UCLA-SO-M14, NCI-DTP Cat# M14, RRID:CVCL_1395), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270) and small cell lung cancer (SCLC) cell line NCI-N417 (ATCC Cat# CRL-5809, RRID:CVCL_1602) were used.. All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).
Article Title: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response
Article Snippet: Representative melanoma cell line M14 (UCLA-SO-M14, NCI-DTP Cat# M14, RRID:CVCL_1395), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270) and small cell lung cancer (SCLC) cell line NCI-N417 (ATCC Cat# CRL-5809, RRID:CVCL_1602) were used.. All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).
Luciferase:Article Title: Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Article Snippet: Representative melanoma cell line M14 (NCI-DTP Cat# M14, RRID:CVCL_1395), small cell lung cancer cell line NCI-N87 (ATCC Cat# CRL-5822, RRID:CVCL_1603), human leukemia cell line HL6 (ATCC Cat# CCL-240, RRID:CVCL_0002), breast cancer cell line HCC1954 (ATCC Cat# CRL-2338, RRID:CVCL_1259), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), and hepatoblastoma cell line Hep-G2 (ATCC Cat# HB-8065, RRID:CVCL_0027) were purchased.. All the cell lines used were authenticated by short tandem repeat profiling with PowerPlex V.1.2 System (Promega), and periodically tested for mycoplasma infection using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).All the cell lines used were authenticated by short tandem repeat profiling with PowerPlex V.1.2 System (Promega), and periodically tested for mycoplasma infection using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).
Article Title: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Article Snippet: Representative melanoma cell line M14 (UCLA-SO-M14, NCI-DTP Cat# M14, RRID:CVCL_1395), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270) and small cell lung cancer (SCLC) cell line NCI-N417 (ATCC Cat# CRL-5809, RRID:CVCL_1602) were used.. All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).
Article Title: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response
Article Snippet: Representative melanoma cell line M14 (UCLA-SO-M14, NCI-DTP Cat# M14, RRID:CVCL_1395), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270) and small cell lung cancer (SCLC) cell line NCI-N417 (ATCC Cat# CRL-5809, RRID:CVCL_1602) were used.. All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).
Control:Article Title: Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Article Snippet: Representative melanoma cell line M14 (NCI-DTP Cat# M14, RRID:CVCL_1395), small cell lung cancer cell line NCI-N87 (ATCC Cat# CRL-5822, RRID:CVCL_1603), human leukemia cell line HL6 (ATCC Cat# CCL-240, RRID:CVCL_0002), breast cancer cell line HCC1954 (ATCC Cat# CRL-2338, RRID:CVCL_1259), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), and hepatoblastoma cell line Hep-G2 (ATCC Cat# HB-8065, RRID:CVCL_0027) were purchased.. All the cell lines used were authenticated by short tandem repeat profiling with PowerPlex V.1.2 System (Promega), and periodically tested for mycoplasma infection using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).All the cell lines used were authenticated by short tandem repeat profiling with PowerPlex V.1.2 System (Promega), and periodically tested for mycoplasma infection using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).
Article Title: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Article Snippet: Representative melanoma cell line M14 (UCLA-SO-M14, NCI-DTP Cat# M14, RRID:CVCL_1395), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270) and small cell lung cancer (SCLC) cell line NCI-N417 (ATCC Cat# CRL-5809, RRID:CVCL_1602) were used.. All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).
Article Title: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response
Article Snippet: Representative melanoma cell line M14 (UCLA-SO-M14, NCI-DTP Cat# M14, RRID:CVCL_1395), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270) and small cell lung cancer (SCLC) cell line NCI-N417 (ATCC Cat# CRL-5809, RRID:CVCL_1602) were used.. All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).
Derivative Assay:Article Title: Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Article Snippet: Representative melanoma cell line M14 (NCI-DTP Cat# M14, RRID:CVCL_1395), small cell lung cancer cell line NCI-N87 (ATCC Cat# CRL-5822, RRID:CVCL_1603), human leukemia cell line HL6 (ATCC Cat# CCL-240, RRID:CVCL_0002), breast cancer cell line HCC1954 (ATCC Cat# CRL-2338, RRID:CVCL_1259), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), and hepatoblastoma cell line Hep-G2 (ATCC Cat# HB-8065, RRID:CVCL_0027) were purchased.. All the cell lines used were authenticated by short tandem repeat profiling with PowerPlex V.1.2 System (Promega), and periodically tested for mycoplasma infection using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).All the cell lines used were authenticated by short tandem repeat profiling with PowerPlex V.1.2 System (Promega), and periodically tested for mycoplasma infection using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).
Article Title: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Article Snippet: Representative melanoma cell line M14 (UCLA-SO-M14, NCI-DTP Cat# M14, RRID:CVCL_1395), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270) and small cell lung cancer (SCLC) cell line NCI-N417 (ATCC Cat# CRL-5809, RRID:CVCL_1602) were used.. All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).
Article Title: Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response
Article Snippet: Representative melanoma cell line M14 (UCLA-SO-M14, NCI-DTP Cat# M14, RRID:CVCL_1395), osteosarcoma cell line 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270) and small cell lung cancer (SCLC) cell line NCI-N417 (ATCC Cat# CRL-5809, RRID:CVCL_1602) were used.. All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).All the cell lines used were authenticated by short tandem repeat profiling with the PowerPlex 1.2 System (Promega, Cat# DC8942), and periodically tested for mycoplasma infection using MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, Cat# LT07-318).
|
ATCC is a verified supplier 
ATCC manufactures this product 